Efferent Labs Applauds FDA's Shift Away from Animal Testing
Efferent Labs' CytoComm® platform is positioned as a critical enabler of new drug evaluation standards following the FDA's shift from animal testing.
'Our CytoComm® platform provides the dynamic cell-based insight and continuous real-time wireless feedback that traditional animal models simply cannot deliver.'— Bill Rader, CEO Efferent Labs
MOUNT PLEASANT, SC, UNITED STATES, April 17, 2025 / EINPresswire.com / -- Efferent Labs, Inc., a preclinical-stage biodevice company specializing in in vivo cellular data collection, celebrates the U.S. Food and Drug Administration's ( FDA ) groundbreaking move toward reducing reliance on mandatory animal testing for monoclonal antibody therapies and other drug classes. The long-awaited regulatory transformation serves to streamline development and improve patient outcomes and safety, while ultimately lowering costs.
The FDA's plan outlines a strategic shift toward New Approach Methodologies (NAMs) and positions Efferent Labs' revolutionary CytoComm® biosensor platform to support the transition with a human-relevant, wireless, real-time alternative that aligns directly with the FDA's roadmap.
'This is the moment we've been building toward,' said Bill Rader, CEO of Efferent Labs. 'Our CytoComm® platform provides the dynamic cell-based insight and continuous real-time wireless feedback that traditional animal models simply cannot deliver. With today's FDA announcement, Efferent Labs moves from visionary to essential.'
The FDA's pivot to AI-based toxicity and efficacy modeling relies on one critical factor: biologically meaningful, statistically reliable and clinically relevant inputs. However, many preclinical systems fall short of this standard.
The CytoComm® platform addresses these limitations by capturing continuous molecular activity from engineered cell lines in vivo. This enables clean, longitudinal data that supports earlier decision-making, reduces animal use, and improves predictive accuracy—all while laying the foundation for AI modeling that regulators can trust.
CytoComm® directly addresses the FDA's key aims under its new framework:
Reduces animal use by replacing live models with embedded, human-relevant cellular sensors
Accelerates development timelines via continuous real-time monitoring
Improves predictive accuracy by capturing complex pharmacodynamic data
Seamlessly integrates with AI workflows, supported by HookeCA™—Efferent's cloud-based analytics interface, which enables real-time data visualization and regulatory-aligned formatting
As the first implantable cellular biosensor of its kind, CytoComm® provides continuous, high-fidelity molecular data without relying on terminal endpoints or high-stress procedures. This enables researchers to capture detailed pharmacodynamic responses using smaller cohorts, fewer animals, and statistically robust outputs.
'We are proud to be part of the solution,' said Rader. 'The science is ready. The technology is here. And with this regulatory shift, the path is now clear. CytoComm® isn't just the future—it's the answer.'
For more information or partnership inquiries, visit http://www.efferentlabs.com
About Efferent Labs
Efferent Labs is pioneering the future of preclinical drug testing with its real-time cellular biosensor platform, CytoComm® Designed to replace static animal-based endpoints, CytoComm® delivers dynamic, high-fidelity cell-based insights—saving time, reducing costs, and elevating both human safety and ethical standards.
Kerry Welch
TRIO
+1 8084290548
email us here
Visit us on social media:
Facebook
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
TRUE MOVEMENT TECH ACQUIRES MANCINO MATS
Expanding U.S. Manufacturing to Build the Future of Active Play SAN DIEGO, June 10, 2025 /PRNewswire/ -- True Movement Tech, a fast-growing leader in sport entertainment innovation and North American manufacturing, today announced the acquisition of Mancino Manufacturing Co., Inc a respected U.S. manufacturer of premium safety padding and equipment for gymnastics, cheer, martial arts, and other sports facilities. This acquisition reinforces True Movement Tech's longstanding commitment to local-first production while expanding its ability to serve movement and play businesses with high-performance, end-to-end solutions. Mancino Mats brings decades of expertise in safety padding, further elevating True Movement Tech's capacity to meet the demands of active environments where safety, durability, and performance are paramount. True Movement Tech President Joe Gram said: Across all sport and play markets, customers are demanding professional and trustworthy service that they can count on throughout the lifetime of their sport business. By joining with Mancino, we are adding a company with decades of experience and success in the safety padding space that - when combined with True Movement Tech's other offerings - allows us to deliver domestically manufactured sport products that are beyond what anyone else is currently capable of. With this latest addition, True Movement Tech now operates six complementary businesses—True Movement Tech, AirTrack™, Superior Trampoline Manufacturing, XR Sports, SDUNITED Training Center, and now Mancino Mats—creating a unified family of design, manufacturing, and installation experts. True Movement Tech is accelerating its mission to shape the future of active play and cementing its role as a trusted leader in the sports entertainment manufacturing industry. ABOUT TRUE MOVEMENT TECH True Movement Tech is a leading manufacturer in the active play and sports entertainment industry, specializing in the design, production, and installation of globally adopted and customer-loved attractions. True Movement Tech first became known when they transformed the trampoline market with their AirTrack Sport Courts and high-design AirBags now universally adopted across the trampoline industry. They have continued to evolve into a proven, reliable partner for business owners and brands from concept to installation to post opening service. True Movement Tech operates six complementary businesses: True Movement Tech, AirTrack™, Superior Trampoline Manufacturing, XR Sports, SDUNITED Training Center, and now Mancino Mats—together forming a global force of manufacturing and design experts. True Movement Tech is headquartered in San Marcos, CA. For more information, please visit: ABOUT MANCINO MATS For over 60 years, Mancino Mats has been a trusted name in American-made safety padding and sports equipment for gymnastics, cheer, martial arts, and athletic facilities. Known for its craftsmanship, product durability, and customer-first service, Mancino has earned the loyalty of coaches, gym owners, and athletic directors across the country. With deep industry expertise and a legacy of innovation, Mancino continues to set the standard for quality and safety in movement-based environments. Now part of the True Movement Tech family, Mancino Mats is proud to help shape the future of active play through expanded capabilities and continued U.S. manufacturing excellence. For more information, please visit: For questions or further inquiries please contact:info@ I 408-569-9504 View original content to download multimedia: SOURCE True Movement Tech Sign in to access your portfolio


Business Wire
an hour ago
- Business Wire
Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor
PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received a purchase order and first payment from Hangzhou Dongye Medical Technology Company Ltd (HDMT) for 35 LuViva systems. HDMT will order directly from Guided Therapeutics and the devices will be assembled and tested by Guided Therapeutics' Chinese partner, Shandong Yaohua Medical Instrument Corporation (SMI). HDMT is in Hangzhou City, Zhejiang Province, where it is the exclusive gynecology products provider for 42 hospitals that perform approximately two million cervical cancer screenings annually. Said Yang Dongye, CEO of HDMT: 'We are extremely impressed with the performance of LuViva and our goal is to eventually replace the current screening tests with LuViva.' The purchase order for $700,000 is to supply HDMT with 35 systems over the next eight months starting in July of this year. 'We are extremely pleased to be working with HDMT to bring LuViva to Zhejiang Province and anticipate making initial shipments next month,' added Mark Faupel, Guided Therapeutics' CEO. 'Working directly with an exclusive provider of gynecology products that can potentially conduct two million LuViva tests each year is a major advance for GTI.' About Guided Therapeutics Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company's first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: The Guided Therapeutics LuViva ® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc. Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading 'Risk Factors' in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and subsequent filings.


Bloomberg
an hour ago
- Bloomberg
FDA Pauses Trials of Gilead HIV Combination After Safety Signal
Gilead Sciences Inc. said federal regulators had placed on hold trials of a new experimental once-weekly HIV drug combination therapy after white blood cell counts dropped in some of the patients. The studies were testing two experimental HIV drugs, GS-1720 and GS-4182, when given together. Gilead said the Food and Drug Administration paused the trials due to a ' safety signal ' triggered by a decrease in lymphocyte levels in some patients given the therapy. Lymphocytes are a type of white blood cell that play a critical role in the immune system's ability to fight infections.